N-terminal scFv multispecific binding molecules

Patent metadata

Field	Value
Publication number	US-12240908-B2
Application number	US-202217726950-A
Country	US
Kind code	B2
Filing date	Apr 22, 2022
Priority date	Nov 5, 2019
Publication date	Mar 4, 2025
Grant date	Mar 4, 2025

Abstract

Multispecific binding molecules (MBMs) comprising an N-terminal scFv, a first Fab and a second Fab, MBM conjugates comprising the MBMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the MBMs and MBM conjugates, methods of using the MBMs, MBM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the MBMs, cells engineered to express the MBMs, and methods of producing MBMs.

First claim

What is claimed is:

1. A trivalent multispecific binding molecule (MBM), comprising:
(a) a first polypeptide chain comprising in an N-to C-terminal orientation:
(i) an scFv comprising means for binding to human amyloid precursor-like protein 2 (APLP2);
(ii) a linker;
(iii) a first heavy chain region of a first Fab comprising means for binding to human fibroblast growth factor receptor 3 (FGFR3); and
(iv) a first Fc domain; and

(b) a second polypeptide chain comprising, in an N-to C-terminal orientation:
(i) a second heavy chain region of a second Fab comprising means for binding to human FGFR3; and
(ii) a second Fc domain capable of heterodimerizing with the first Fc domain to form an Fc heterodimer;

(c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form the first Fab; and
(d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form the second Fab.

2. The trivalent MBM of claim 1 , wherein the linker is at least 5 amino acids in length.

3. The trivalent MBM of claim 2 , wherein the linker is up to 40 amino acids in length.

4. The trivalent MBM of claim 3 , wherein the linker is 25 to 35 amino acids in length.

5. The trivalent MBM of claim 3 , wherein the linker is or comprises a multimer of GnS (SEQ ID NO: 61) or SGn (SEQ ID NO: 62), where n is an integer from 1 to 7.

6. The trivalent MBM of claim 5 , wherein the linker is or comprises a multimer of G4S (SEQ ID NO: 4).

7. The trivalent MBM of claim 1 , wherein the Fc domains in the Fc heterodimer comprise knob-in-hole mutations as compared to a wild type Fc domain.

8. The trivalent MBM of claim 1 , wherein at least one Fc domain in the Fc heterodimer comprises a star mutation as compared to a wild type Fc domain.

9. A composition comprising the trivalent MBM of claim 1 and an excipient.

10. The trivalent MBM of claim 1 , wherein the linker is attached to the first heavy chain region of the first Fab.

Assignees

• Regeneron Pharma

Inventors

• Shen Yang
• Lee Ann-Hwee
• Yang Yan
• Lin Chia-Yang

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title

• C07K2317/35

  Valency · CPC title

• C07K2317/622

  Single chain antibody (scFv) · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title